1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly’s Weekly Insulin Efsitora Hits Mark In Two Trials, With Three More To Go

 
• By Alaric DeArment

The QWINT-2 and QWINT-4 trials showed non-inferiority to daily insulin, but efsitora will likely hit the market sometime after competitor Novo Nordisk’s Awiqli.

• Source: Shutterstock

Eli Lilly and Company has taken another step toward competing in the market for once-weekly insulin to treat patients with type 2 diabetes with positive results from Phase III trials of efsitora alfa. But it still has a way to go before it is ready for that competition to take place, and by then, its main competitor will have likely become the first to market.

Lilly announced 16 May topline results from the QWINT-2 and QWINT-4 trials evaluating efsitora in adults with type 2 diabetes using insulin for the first time and those who require...

Key Takeaways

  • Lilly announced positive data from two Phase III trials in the QWINT program of efsitora, its once-weekly insulin for type 2 diabetes, showing non-inferiority to daily...

More from Clinical Trials

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By Mandy Jackson

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

More from R&D

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.